Stock Research for EPZM

EPZM

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

EPZM Stock Chart & Research Data

The EPZM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EPZM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


EPZM Due diligence Resources & Stock Charts

The EPZM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EPZM Detailed Price Forecast - CNN Money CNN View EPZM Detailed Summary - Google Finance
Yahoo View EPZM Detailed Summary - Yahoo! Finance Zacks View EPZM Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View EPZM Trends & Analysis - Trade-Ideas Barrons View EPZM Major Holders - Barrons
NASDAQ View EPZM Call Transcripts - NASDAQ Seeking View EPZM Breaking News & Analysis - Seeking Alpha
Spotlight View EPZM Annual Report - CompanySpotlight.com OTC Report View EPZM OTC Short Report - OTCShortReport.com
TradeKing View EPZM Fundamentals - TradeKing Charts View EPZM SEC Filings - Bar Chart
WSJ View Historical Prices for EPZM - The WSJ Morningstar View Performance/Total Return for EPZM - Morningstar
MarketWatch View the Analyst Estimates for EPZM - MarketWatch CNBC View the Earnings History for EPZM - CNBC
StockMarketWatch View the EPZM Earnings - StockMarketWatch MacroAxis View EPZM Buy or Sell Recommendations - MacroAxis
Bullish View the EPZM Bullish Patterns - American Bulls Short Pains View EPZM Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View EPZM Stock Mentions - StockTwits PennyStocks View EPZM Stock Mentions - PennyStockTweets
Twitter View EPZM Stock Mentions - Twitter Invest Hub View EPZM Investment Forum News - Investor Hub
Yahoo View EPZM Stock Mentions - Yahoo! Message Board Seeking Alpha View EPZM Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for EPZM - SECform4.com Insider Cow View Insider Transactions for EPZM - Insider Cow
CNBC View EPZM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EPZM - OTC Markets
Yahoo View Insider Transactions for EPZM - Yahoo! Finance NASDAQ View Institutional Holdings for EPZM - NASDAQ


Stock Charts

FinViz View EPZM Stock Insight & Charts - FinViz.com StockCharts View EPZM Investment Charts - StockCharts.com
BarChart View EPZM Stock Overview & Charts - BarChart Trading View View EPZM User Generated Charts - Trading View


Latest Financial News for EPZM

Stock Performance Review on Exelixis and Three Other Biotech Stocks
Posted on Thursday June 21, 2018

Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Endocyte Inc. (NASDAQ:ECYT), Epizyme Inc. (EPZM), Esperion Therapeutics Inc. (ESPR), and Exelixis Inc. (EXEL).All you have to do is sign up today for this free limited time offer by clicking the link below. West Lafayette, Indiana headquartered Endocyte Inc.'s stock finished Wednesday's session 3.46% higher at $14.64.


Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)
Posted on Friday June 15, 2018

Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, announced positive interim data from an ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor, as a monotherapy for patients with relapsed or refractory follicular lymphoma (FL). The data, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, show that tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in these heavily pre-treated patients. Interim data as of May 1, 2018 included 82 evaluable patients across two cohorts, prospectively assigned by EZH2 status.


Why Is Epizyme (EPZM) Up 16.2% Since Its Last Earnings Report?
Posted on Thursday June 07, 2018

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners, Perrigo Company plc, Epizyme, and Landec — Future Expectations, Projections Moving into 2018
Posted on Wednesday June 06, 2018

NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Silicon ...


Enter a stock symbol to view the stock details.